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Conclusion: Ventilator support and/or acute renal failure at the time of LT are
major predictors of mortality but complex recipients/donors relationships may
moderate these associations, as demonstrated by our CART analysis.
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The national protocol for the cDCD program authorized in France since 2014
includes selection criteria as donor age ≤60 years, functional warm ischemia
time (fWIT) <30 min (liver), <90 min (lung), <120 min (kidney), in situ kidney
perfusion performed by normothermia regional perfusion (nRP), machine
perfusion use (except liver) and short cold ischemia times (CIT). Only non-
urgent recipients awaiting a 1st transplant were eligible.
The aim of this study was to compare primary non function (PNF), delayed
graft function (DGF) and length of stay in hospital after kidney transplantation
(KTR) according to 2 types of donors: cDCD (53 KTR from 12/2014 to 5/2016)
and brain death donors (DBD) aged ≤60 years (3756 KTR from 1/2013 to 4/
2016), only for patients awaiting 1st transplant.
Out of 60 potential cDCD donors, 29 have been retrieved, mean age
48 years. Causes of death are mainly hypoxic brain damage (48%) and
trauma/head injury (26%). Procurement failure are secondary to Relative’s
opposition (30%), agonal delay >180 min (7.6%) and logistical problem (7.6%).
Mean fWIT are 30 min (kidney), 21 min (liver) and 85 min (lung). nRP was
used in all utilized donors after mean circulatory arrest delay of 25 min. Mean
renal CIT is 10.7 h.
Rate of PNF (2%), mean creatinin (150 vs 176 µmol/l) and renal clearance
(54 vs 47 ml/mn) at discharge are comparable. DGF rate (3.4% vs 19.5%),
dialysis number and length of stay in hospital are significantly improved in case
of cDCD. 13 liver transplants and 1 lung transplant are also performed without
EAD.
These good results ensue from national and consensual protocol, with aim
to limit war ischemia times and injuries, thanks to nRP use, optimal graft
preservation and recipient selection. cDCD program represents an optimal and
additional source of valuable transplants.
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Introduction: Due to the shortage of and/or lack of access to deceased
donors, living donor liver transplantation (LDLT) has contributed to allow the
transplantation of children in a timely fashion regarding the evolution of their
diseases. We reviewed our 23 years experience in LDLT.
Patients and Methods: Between July 1993 and December 2015, 350 LDLT
were performed (median age: 1.25 years; range: 0.3–16.5 years). The first
indication for LT was biliary atresia (n = 218, 62%).
Results: No mortality or persisting disability was encountered in the 350 living
donors of this series. Overall patient and graft survivals in the recipients were
96% and 95% at one year, and 94% and 92% at five years, respectively. The
retransplantation rate was 8/350 (2.3%), including two children who finally died.
No ABO-incompatible graft was lost in this series. To better evaluate our
learning curve, the results were further analyzed considering five eras. A
striking feature was the progressive increase of the proportion of LDLT/total
paediatric LT along the eras as follows: 1993–7: 57/152 (38%); 1998–2001: 38/
100 (38%); 2002–7: 66/161 (41%); 2008–11: 80/101 (79%); 2012–15: 108/122
(88%). When comparing 1993–7 and 2007–11 eras, 5 year patient and graft
survival rates increased from 89% to 98%, and 86% to 96%, respectively.
Conclusions: Our results indicate: (1) the increasing recourse to LDLT at our
pediatric LT program; (2) the safety of living donor surgery and management;
(3) the improvement of overall results of LDLT along the eras; (4) the judicious
use of ABO-incompatible LDLT due to an adequate protocol for isoagglutinin
depletion. A detailed assessment of the risks/benefits balance of steroid-free
immunosuppression in pediatric LT is ongoing.
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HLA allo-immunization is caused by sensitization events such as transfusions,
pregnancies or previous transplantations. The objective of our work was to
analyze the consequences of each sensitization event on HLA immunization
and on access to transplantation.
We investigated HLA immunization (by Luminex single bead Ag, One
lambda, positivity if MFI > 1000) of 461 patients registered on the waiting list
between 01/01/2009 and 31/12/2013, with only one type of sensitization event
(123 transfused, 68 with pregnancies, 19 previous transplants) or without
sensitization event (251 patients; control group).
The percentage of immunized patients was respectively 41% in the control
group, 39% in the transfused group, 59% in group pregnancy, 89% in the
transplantation group (p < 0.001) for class I HLA antibodies, and 26%, 25%,
43% and 83% (p < 0.001) for class II HLA antibodies. The mean number of
anti-HLA specificities (class I and class II) was respectively 1.6 ! 3.0 ;
2.2 ! 6.1 ; 8.5 ! 15.5 ; 27.4 ! 8.9 (p < 0.001). Mean MFI were
2385 ! 1931 ; 2245 ! 1729 ; 3036 ! 3375 ; 5697 ! 4784 (p < 0.001) for
class I antibodies and mean MFI were 2031 ! 1456 ; 2013 ! 1346 ;
4321 ! 4346 ; 9102 ! 6870 (p < 0.001) for class II antibodies. cPRA (calcu-
lated Panel Reactive Antibodies) were 10%, 12%, 35% and 65%
(p < 0.001) for the different groups respectively. At 01.05.2016, 89% in the
control group, 85% in the group transfused, 85% in the group pregnancy but
only 47% in the group transplantation were transplanted (p < 0.001). Mean
waiting time (month) was 20.3 ! 16.0, 23.6 ! 18.7, 24.8 ! 18.2 et
29.1 ! 20.3 in the different groups respectively (p = 0.006).
HLA immunization risk depends on the sensitization event. Previous
transplantations had the strongest effect on HLA immunisation and significantly
restricted the access to a new transplant, followed by pregnancies. The
prevalence of HLA sensitization in the transfusion group is not very different
compare to the group without classical sensitization event.
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Introduction: Donation after circulatory death (DCD) has been proposed to
partially overcome the organ donor shortage. DCD-LT remains controversial,
with reported increased risk of graft loss and retransplantation. The authors
retrospectively reviewed a single centre experience with controlled DCD-LT in
a 14-year period.
Patients and Methods: 125 DCD-LT were consecutively performed between
2003 and 2016. All donation and procurement procedures were performed as
controlled DCD in operative rooms. Data are presented as median (ranges).
Median donor age was 56 years (16–84). Most grafts were flushed with HTK
solution in the first part of experience, and more recently with IGL1. Allocation
was centre-based. Median follow-up was 52 (1–164) months. No patient was
lost to follow-up.
Results: Median total DCD warm ischemia was 19 min (9–39). Median cold
ischemia was 238 min (105–576). Patient survivals were 90.2%, 77.5% and
74.5 % at 1.3 and 5 years, respectively. Graft survivals were 87.7%, 76.3% and
73.2% at 1.3 and 5 years, respectively. Biliary complications included anas-
tomotic strictures and extrahepatic main bile duct ischemic obstruction, that
were managed either by endoscopy or hepatico-jejunostomy. No PNF was
observed in this series and one graft was lost due to ischemic cholangiopathy.
Discussion: In this series, DCD LT appears to provide results similar to
classical LT. Short cold ischemia and recipient selection with low MELD score
may be the keys to good results in DCD LT, in terms of graft survival and
avoidance of ischemic cholangiopathy.
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